Article Text

Download PDFPDF
Original research
Comparison of three commonly used CT perfusion software packages in patients with acute ischemic stroke
  1. Miou S Koopman1,
  2. Olvert A Berkhemer1,2,3,
  3. Ralph R E G Geuskens4,
  4. Bart J Emmer1,
  5. Marianne A A van Walderveen5,
  6. Sjoerd F M Jenniskens6,
  7. Wim H van Zwam7,
  8. Robert J van Oostenbrugge8,
  9. Aad van der Lugt2,
  10. Diederik W J Dippel3,
  11. Ludo F Beenen1,
  12. Yvo B W E M Roos9,
  13. Henk A Marquering1,4,
  14. Charles B L M Majoie1
  15. on behalf of the MR CLEAN Trial Investigators
    1. 1Department of Radiology and Nuclear Medicine, Amsterdam UMC, location AMC, Amsterdam, The Netherlands
    2. 2Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    3. 3Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    4. 4Department of Biomedical Engineering and Physics, Amsterdam UMC, location AMC, Amsterdam, The Netherlands
    5. 5Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
    6. 6Department of Radiology, Radboud University Medical Center, Nijmegen, The Netherlands
    7. 7Department of Radiology and CArdiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands
    8. 8Department of Neurology and CArdiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands
    9. 9Department of Neurology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands
    1. Correspondence to Miou S Koopman, Radiology and Nuclear Medicine, Amsterdam UMC, location AMC, Amsterdam 1105 AZ, The Netherlands; m.s.koopman{at}amc.uva.nl

    Footnotes

    • Contributors The MR CLEAN trial was designed by WHZ, AvdL, RJvO, DWJD, YBWEMR, and CBLMM. OAB collected and prepared the data for the trial. OAB, RREGG, MAAvW, and SFJ collected the data for this study. MSK conducted the statistical analysis, interpreted the results, and drafted the paper. HAM and BJE assisted with the statistical analysis, interpretation of the results, and drafting the paper. OAB, MAAvW, SFJ, WHZ, RJvO, AvdL, DWJD, LFB, YBWEMR, and CBLMM critically revised the paper. All authors approved the version to be published.

    • Funding The MR CLEAN trial was partly funded by the Dutch Heart Foundation, grant no 2008T30, and by unrestricted grants from AngioCare BV, Medtronic/Covidien/EV3,MEDAC Gmbh/LAMEPRO, Penumbra, Stryker, and Top Medical/ Concentric.

    • Competing interests Amsterdam UMC, location AMC received funds from Stryker for consultations by CBLMM, YBWEMR, and OAB. CBLMM received research grants from CVON/Dutch Heart Foundation, European Commission and Twin Foundation. HAM, RREGG, CBLMM, and YBWEMR are shareholders of Nico.lab, a company that focuses on the use of artificial intelligence for medical image analysis. Erasmus MC received funds from Bracco Imaging for consultations by DWJD. Erasmus MC received funds from CVON/Dutch Heart Foundation, European Commission, Stryker, Penumbra, and Medtronic for the execution of stroke trials by DWJD and AvdL. Maastricht University Medical Center received funds from Stryker and Cerenovus for consultations by WHZ.

    • Ethics approval A central medical ethics committee and the research boards of all participating centers accepted the MR CLEAN trial.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Because of the sensitive nature of the data collected for this study, requests to access the data set may be sent to the MR CLEAN executive committee (https://www.mrclean-trial.org/).

    • Patient consent for publication Obtained.

    View Full Text

    Statistics from Altmetric.com

    Footnotes

    • Contributors The MR CLEAN trial was designed by WHZ, AvdL, RJvO, DWJD, YBWEMR, and CBLMM. OAB collected and prepared the data for the trial. OAB, RREGG, MAAvW, and SFJ collected the data for this study. MSK conducted the statistical analysis, interpreted the results, and drafted the paper. HAM and BJE assisted with the statistical analysis, interpretation of the results, and drafting the paper. OAB, MAAvW, SFJ, WHZ, RJvO, AvdL, DWJD, LFB, YBWEMR, and CBLMM critically revised the paper. All authors approved the version to be published.

    • Funding The MR CLEAN trial was partly funded by the Dutch Heart Foundation, grant no 2008T30, and by unrestricted grants from AngioCare BV, Medtronic/Covidien/EV3,MEDAC Gmbh/LAMEPRO, Penumbra, Stryker, and Top Medical/ Concentric.

    • Competing interests Amsterdam UMC, location AMC received funds from Stryker for consultations by CBLMM, YBWEMR, and OAB. CBLMM received research grants from CVON/Dutch Heart Foundation, European Commission and Twin Foundation. HAM, RREGG, CBLMM, and YBWEMR are shareholders of Nico.lab, a company that focuses on the use of artificial intelligence for medical image analysis. Erasmus MC received funds from Bracco Imaging for consultations by DWJD. Erasmus MC received funds from CVON/Dutch Heart Foundation, European Commission, Stryker, Penumbra, and Medtronic for the execution of stroke trials by DWJD and AvdL. Maastricht University Medical Center received funds from Stryker and Cerenovus for consultations by WHZ.

    • Ethics approval A central medical ethics committee and the research boards of all participating centers accepted the MR CLEAN trial.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Because of the sensitive nature of the data collected for this study, requests to access the data set may be sent to the MR CLEAN executive committee (https://www.mrclean-trial.org/).

    • Patient consent for publication Obtained.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.